NasdaqGS:CYTKBiotechs
Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation
Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference.
The updates covered exercise capacity outcomes, effectiveness across patients with and without hypertension, and safety during treatment interruption and restart.
The new analyses expand the clinical profile of MYQORZO, a recently approved oHCM therapy, and add detail on how the drug performs in real treatment scenarios.
Cytokinetics...